Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer

Since 2010, six drugs have been approved for the treatment of castration-resistant prostate cancer, i.e., CYP17 inhibitor Abiraterone, androgen receptor antagonist Enzalutamide, cytotoxic agent Cabazitaxel, vaccine Sipuleucel-T, antibody Denosumab against receptor activator of nuclear factor kappa B...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Lina, Hu, Qingzhong, Hartmann, Rolf W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742227/
https://www.ncbi.nlm.nih.gov/pubmed/23880851
http://dx.doi.org/10.3390/ijms140713958

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742227/
https://www.ncbi.nlm.nih.gov/pubmed/23880851
http://dx.doi.org/10.3390/ijms140713958

Ejemplares similares